Problem

ALP Bio targets immunogenicity in biologic drugs, especially the risk that therapeutic antibodies trigger unwanted anti-drug antibody (ADA) responses. These responses can reduce treatment effectiveness, create safety and dosing complications, and turn a promising antibody into a late-stage development problem. The economic pain is substantial: bringing a new biotherapeutic to market is estimated to cost about $2.6 billion when failed candidates are included, while development typically takes a decade or more. The killer use case is therefore early antibody lead selection and optimization—finding immune liabilities before expensive clinical development, rather than discovering them after years of investment.

Product / Service

ALP Bio combines human tonsil-derived immune organoids with protein-focused generative AI. Its ex vivo tonsil organoid assay models immune interactions associated with ADA formation and generates population-level information about how different patients may respond. The AI then scores immunogenicity risk and can redesign flagged antibody sequences to preserve function while reducing the likelihood of an unwanted immune response, using an iterative loop between computational design, laboratory testing, and ex vivo validation.

The company appears to offer a hybrid platform and services model: AI-based in-silico ADA scoring can be licensed, while customers can purchase asset-level tonsil-organoid risk reports or engage ALP Bio for broader antibody optimization, asset rescue, screening, re-engineering, and co-development programs. The intended benefit is earlier, human-relevant evidence that improves candidate selection, reduces downstream uncertainty, and makes immunogenicity an actionable design parameter.

Market

ALP Bio operates in biologics discovery and development, specifically the immunogenicity-risk assessment, antibody engineering, and preclinical drug-de-risking markets. Its competitive set is not limited to a single direct peer: alternatives include computational immunogenicity tools such as EpiVax’s JanusMatrix, established immunogenicity-assay and antibody-engineering providers such as Abzena, and CROs offering ADA assays such as Oncodesign Services. ALP Bio’s differentiation is the combination of human tonsil organoid readouts with generative protein AI, rather than relying only on conventional assays or purely in-silico scoring.

The company is early commercial and appears pre-revenue or at least pre-scale based on the public evidence reviewed: no revenue or named completed customer contract is disclosed, while the company is engaging pharma and biotech partners for early-access collaborations and first pilot projects. Its disclosed traction is a $2.2 million pre-seed round led by 42CAP, additional Venture Kick support, and a stated plan to expand organoid automation and throughput, launch partner projects, and build commercial capacity in Switzerland and the United States.